PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for December 16, 2005 Subscribe to this News Feed    
 

FDA-Approved Hemor~Rite Cryotherapy for Hemorrhoid Relief -FAMA Holdings Officially Launches Website to Offer Easy Online Access

FAMA Holdings International Corporation, a Florida based medical device company and maker of the Hemor~Rite™ Cryotherapy medical device for the treatment of hemorrhoids, announced that on December 26, 2005, the company will open its state of the art worldwide distribution center which will distribute FAMA Holdings International Corporation’s innovative and exciting line of healthcare products into the worldwide markets.

Miramar, Fla. (PRWEB) December 16, 2005 -- FAMA Holdings International Corporation, a Florida based medical device company and maker of the Hemor~Rite™ Cryotherapy medical device for the treatment of hemorrhoids, announced that on December 26, 2005, the company will open its state of the art worldwide distribution center which will distribute FAMA Holdings International Corporation’s innovative and exciting line of healthcare products into the worldwide markets.

The company has selected Miramar , Florida as the headquarters for its distribution center, which will begin delivery of FAMA Holdings products on December 26, 2005 , offering domestic and international shipping.

“The launch of our website symbolizes the beginning of relief for so many hemorrhoid sufferers that seek a convenient and discreet manner to alleviate such a common and uncomfortable condition,” said Frank Melendez, President and CEO of FAMA Holdings International Corporation.

FAMA Holdings International Corporation will officially launch its website, www.hemorrite.com, for the distribution of its products aiming to provide therapeutic relief for the millions of people suffering from hemorrhoids.

The comprehensive website will provide useful information concerning the development and treatment of hemorrhoids and will be a resource for those suffering with this ailment to access practical data and support. It will also provide a safe manner in which consumers can order any of FAMA Holding’s products and have them delivered directly to their home in a discreet manner.

FAMA Holdings received U.S. Food and Drug Administration (FDA) 510k approval to market its new Hemor~Rite™ Cryotherapy, an anatomically designed device for applying cold therapy (Cryotherapy) directly to the swollen hemorrhoidal veins of external hemorrhoids and the internal hemorrhoids within the rectal cavity, providing prompt relief of itching, pain, and swelling. Over 46% of Americans suffer from hemorrhoids including individuals suffering from stress, pregnant women, weight lifters and others. Hemor~Rite™ Cryotherapy has been designed taking into consideration human anatomy and medical concepts of cryotherapy. The device, which represents an important new addition to FAMA Holding's line of healthcare products. Currently, the device may be ordered directly from the company by calling 1-866-HEMORITE (1-866-436-6747).

FAMA Holdings also manufactures and markets Colon-Rite a dietary supplement for support of normal colon function and plans to launch additional lines of dietary supplements within the next few months. For more information visit www.hemorrite.com

###

Technorati Tags

Bookmark -  Del.icio.us | Furl It | Technorati | Ask | MyWeb | Propeller | Live Bookmarks | Newsvine | TailRank | Reddit | Slashdot | Digg | Stumbleupon | Google Bookmarks | Sphere | Blink It | Spurl


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
Email this story to a colleague
CONTACT INFORMATION
Angela Melendez
FAMA Holdings International Corporation
866.436.6748
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.